One-year reductions in cisplatin-related chronic kidney disease (CKD) in patients with head and neck (HNC) cancer treated with avasopasem manganese: A prespecified analysis from the phase 3 ROMAN trial.-MedSci.cn

One-year reductions in cisplatin-related chronic kidney disease (CKD) in patients with head and neck (HNC) cancer treated with avasopasem manganese: A prespecified analysis from the phase 3 ROMAN trial.

Allen, BG; Spitz, DR; Mapuskar, KA; Zepeda-Orozco, D; Beardsley, RA; Kennedy, EP; Anderson, CM

JOURNAL OF CLINICAL ONCOLOGY, 2023; 41 (16):

科室
- - 订阅+
  - 更多科室
工具
服务